Abcellera Biologics Inc (ABCL)

$3.65 +0.08 (2.24%)
Market Cap 1.07B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 1,548,165
Avg Vol 4,450,218
Day's Range N/A - N/A
Shares Out 303.16M
Stochastic %K 61%
Beta 0.84
Analysts Strong Sell
Price Target $8.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Kaykay610
Kaykay610 Mar. 11 at 10:25 PM
$ABCL kymera therapeutics valuation is based on phase 1 data and cash but need less to say the degrader space is bout to take off and our leaders are trying to position itself for the long run you have to see the way the chess pieces are moving!
0 · Reply
tradersunion353
tradersunion353 Mar. 11 at 3:30 PM
$ABCL Boring performance as usual
0 · Reply
Hofgrouuunder
Hofgrouuunder Mar. 11 at 2:41 PM
$ABCL bought 20k shares today. belive in the company long term. LFG
1 · Reply
DeMampCamp
DeMampCamp Mar. 11 at 2:37 PM
$ABCL Happy Hump Day folks, nice trading so far this morning with the ugly indexes red! I'm still expecting a very big year here for us, I expect our PPS to gradually increase as we get closer to our phase 2 readout! Cheers!
1 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 11 at 12:50 PM
$ABCL
0 · Reply
DragonAlgo
DragonAlgo Mar. 11 at 8:38 AM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.35 Stop: $0.25 TP1: $0.45 TP2: $0.59 TP3: $0.84 🔗 https://dragonalgo.com
0 · Reply
Samb2344
Samb2344 Mar. 10 at 9:37 PM
$ABCL give us the $4
0 · Reply
PorkchopSquats
PorkchopSquats Mar. 10 at 8:12 PM
$PRME $NTLA $CRSP $BEAM $ABCL Been boring for the past 7 months. Eventually it won’t be anymore. 50% up or down will happen, this has been the time to place your wager on direction. GL to all.
0 · Reply
Kaykay610
Kaykay610 Mar. 10 at 7:57 PM
$ABCL good shout out from prelude at conference
2 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 10 at 7:35 PM
$ABCL
1 · Reply
Latest News on ABCL
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 6, 2026, 3:15 PM EST - 5 days ago

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:27 PM EST - 14 days ago

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 15 days ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 4 weeks ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 6 weeks ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 9:16 PM EST - 7 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 2 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 2 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 3 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 8, 2025, 1:37 PM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 3 months ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 4 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 4 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 4 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 5 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 6 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 7 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 10 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 10 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 10 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 10 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 10 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 11 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Kaykay610
Kaykay610 Mar. 11 at 10:25 PM
$ABCL kymera therapeutics valuation is based on phase 1 data and cash but need less to say the degrader space is bout to take off and our leaders are trying to position itself for the long run you have to see the way the chess pieces are moving!
0 · Reply
tradersunion353
tradersunion353 Mar. 11 at 3:30 PM
$ABCL Boring performance as usual
0 · Reply
Hofgrouuunder
Hofgrouuunder Mar. 11 at 2:41 PM
$ABCL bought 20k shares today. belive in the company long term. LFG
1 · Reply
DeMampCamp
DeMampCamp Mar. 11 at 2:37 PM
$ABCL Happy Hump Day folks, nice trading so far this morning with the ugly indexes red! I'm still expecting a very big year here for us, I expect our PPS to gradually increase as we get closer to our phase 2 readout! Cheers!
1 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 11 at 12:50 PM
$ABCL
0 · Reply
DragonAlgo
DragonAlgo Mar. 11 at 8:38 AM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.35 Stop: $0.25 TP1: $0.45 TP2: $0.59 TP3: $0.84 🔗 https://dragonalgo.com
0 · Reply
Samb2344
Samb2344 Mar. 10 at 9:37 PM
$ABCL give us the $4
0 · Reply
PorkchopSquats
PorkchopSquats Mar. 10 at 8:12 PM
$PRME $NTLA $CRSP $BEAM $ABCL Been boring for the past 7 months. Eventually it won’t be anymore. 50% up or down will happen, this has been the time to place your wager on direction. GL to all.
0 · Reply
Kaykay610
Kaykay610 Mar. 10 at 7:57 PM
$ABCL good shout out from prelude at conference
2 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 10 at 7:35 PM
$ABCL
1 · Reply
UncleTomFlorida
UncleTomFlorida Mar. 10 at 7:32 PM
$ABCL Company appears to me that it is executing its business plan superbly well. Its model is for strong balance sheet, low real estate costs, and secure, long term growth free of market mood swings or failure ofvany one molecule. I’m admittedly overweight in this stock, with significant paper losses. Nevertheless, $ABCL’s prospects appear to me to be so good that I add to my stash almost every day that market price is below my average cost per share.
1 · Reply
tradersunion353
tradersunion353 Mar. 10 at 5:47 PM
$ABCL ABCL time tis reward long term investors who wanna make money . Time to move your a$S Who want to hold for a decade keep adding they are okay but rest all needs to be rewarded soon
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Mar. 10 at 4:11 PM
$ABCL Ready for a zero on the end, come on baby daddy needs some new shoes
1 · Reply
snowPOW
snowPOW Mar. 10 at 3:59 PM
$ABCL if Carl can follow through, his rough public target is a market cap of about 20B. I think the recent defense announcements from the Canadian government might have some money for them, it looks like it matches Carl's prerogative on the industry and a sovereign bio security for Canada.
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 10 at 3:39 PM
$ABCL Share Price: $3.61 Contract Selected: Oct 16, 2026 $5 Calls Buy Zone: $0.26 – $0.32 Target Zone: $0.43 – $0.52 Potential Upside: 59% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SpartanAlerts
SpartanAlerts Mar. 10 at 3:34 PM
$FPS looks like $33 was a good entry. Other ones I’m extremely bullish on long term… $IREN $TMC $ASPI $ABCL
2 · Reply
DragonAlgo
DragonAlgo Mar. 10 at 1:59 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-03-20 | Strike: $4.00 | Type: CALL Option Plan (premium): Entry: $0.15 Stop: $0.11 TP1: $0.20 TP2: $0.26 TP3: $0.36 Volatility regime is active. 🔗 https://dragonalgo.com
0 · Reply
8008track
8008track Mar. 9 at 9:16 PM
$ABCL I’ve watched this talk more times than I care to admit. It has a lot of insightful nuggets. lf you’re interested in learning how Carl Hansen thinks about the industry, AbCellera, capital allocation, and what it takes to become a big player in biotech, it’s worth a listen. It has helped me solidify my conviction in Hansen and the company and makes me think like an owner - long term. Only risk what you’re willing to lose but this can get explosive. The potential is massive. Tip - if you want to speed up talk, you can go to settings in YouTube and choose desired playback speed. I’ve listened to it in practically every speed setting. https://youtu.be/X8q_qZgqSRw?si=5mAa-yFuSZFhEGBl
3 · Reply
estatebuyersmia
estatebuyersmia Mar. 9 at 4:13 PM
$ABCL $IOVA IS ABOUT TO BE SQUEEZED.. ITS MY BIGGEST POSITION
1 · Reply
tradersunion353
tradersunion353 Mar. 9 at 2:41 PM
$ABCL Disgusting, i understand market is down How about when market is up - does abcl go up . Nope At this time , abcl is overhyped and underperforming. I know few folks here love to see this at $1 or even lower.. so they can add more.
3 · Reply
snowPOW
snowPOW Mar. 9 at 2:34 PM
$ABCL insider buying here!
0 · Reply
8008track
8008track Mar. 9 at 2:16 PM
$ABCL with a successful readout of abcl635, we will be on our way to 100x.
2 · Reply